Search
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB16901ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16904ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16916ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16918ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
ICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalThe drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
Aminacrine
go.drugbank.com/drugs/DB11561InvestigationalIt is also used as an intracellular pH indicator.
Categories: Compounds used in a research, industrial, or household settingPF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
CHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.
Fasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.
Mitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.